{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:16:04Z","timestamp":1783743364902,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Containment policies and other restrictions introduced by the Spanish government in response to the COVID-19 pandemic present challenges for marginalised populations, such as people who use drugs. Harm reduction centres are often linked to social services, mental health services, and infectious disease testing, in addition to tools and services that help to reduce the harms associated with injecting drugs. This study aimed to explore the impact of the pandemic on these services in four autonomous communities in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a cross-sectional study that employed a seven-section structured survey administered electronically to 20 centres in July 2020. Data from the most heavily affected months (March\u2013June) in 2020 were compared to data from the same period in 2019. Averages were calculated with their ranges, rates, and absolute numbers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 11 responding centres reported having had to adapt or modify their services during the Spanish state of alarm (14 March\u201321 June 2020). One centre reported complete closure for 2\u00a0months and four reported increases in their operating hours. The average number of service users across all centres decreased by 22% in comparison to the same period in the previous year and the average needle distribution decreased by 40% in comparison to 2019. Most centres reported a decrease in infectious disease testing rates (hepatitis B and C viruses, human immunodeficiency virus, and tuberculosis) for March, April, and May in 2020 compared to the previous year. Reported deaths as a result of overdose did not increase during the state of alarm, but 2\/11 (18%) centres reported an increase in overdose deaths immediately after finalisation of the state of alarm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, Spanish harm reduction centres were able to continue operating and offering services by adjusting operating hours. The number of overall service users and needles distributed fell during the Spanish state of alarm lockdown period, suggesting that fewer clients accessed harm reduction services during this time, putting them at greater risk of reusing or sharing injecting equipment, overdosing, acquiring infectious diseases with decreased access to testing or discontinuing ongoing treatment such as methadone maintenance therapy, hepatitis C treatment, or antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-020-00432-w","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T19:04:33Z","timestamp":1604430273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The impact of the COVID-19 pandemic on harm reduction services in Spain"],"prefix":"10.1186","volume":"17","author":[{"given":"Camila A.","family":"Picchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Martr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"432_CR1","unstructured":"Worldometer. Coronavirus cases: COVID-19 coronavirus pandemic. Worldometer. 2020 [cited 2020 Aug 12]. pp. 1\u201322. \n                  https:\/\/www.worldometers.info\/coronavirus\/?\n                  \n                ."},{"key":"432_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. The Lancet. 2019;394:1560\u201379.","journal-title":"The Lancet"},{"key":"432_CR3","unstructured":"United Nations Office on Drugs and Crime IN of P who UDUNP on HUNDPUNPFWHOUSA for ID. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. Vienna; 2017 [cited 2020 Aug 12]. \n                  https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2017_HIV-HCV-programmes-people-who-inject-drugs_en.pdf\n                  \n                ."},{"issue":"12","key":"432_CR4","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Heal"},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(16)00619-X","volume":"387","author":"J Csete","year":"2016","unstructured":"Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. The Lancet. 2016;387:1427\u201380.","journal-title":"The Lancet"},{"issue":"3","key":"432_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545\u201363.","journal-title":"Addiction"},{"issue":"4","key":"432_CR7","doi-asserted-by":"publisher","first-page":"e1001625","DOI":"10.1371\/journal.pmed.1001625","volume":"11","author":"Y-F Huang","year":"2014","unstructured":"Huang Y-F, Yang J-Y, Nelson KE, Kuo H-S, Lew-Ting C-Y, Yang C-H, et al. Changes in HIV incidence among people who inject drugs in Taiwan following Introduction of a harm reduction program: a study of two cohorts. PLoS Med. 2014;11(4):e1001625.","journal-title":"PLoS Med."},{"key":"432_CR8","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","volume":"17","author":"AS Abdul-Quader","year":"2013","unstructured":"Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17:2878\u201392.","journal-title":"AIDS Behav"},{"key":"432_CR9","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA update on the implications of COVID-19 for people who use drugs (PWUD) and drug service providers. 2020 [cited 2020 Aug 12]. \n                  https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/12879\/emcdda-covid-update-1-25.03.2020v2.pdf\n                  \n                ."},{"key":"432_CR10","unstructured":"Centers for Disease Control and Prevention. What to know about liver disease and COVID-19|CDC [cited 2020 Aug 12]. \n                  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/liver-disease.html\n                  \n                ."},{"key":"432_CR11","doi-asserted-by":"publisher","first-page":"2000688","DOI":"10.1183\/13993003.00688-2020","volume":"55","author":"JM Leung","year":"2020","unstructured":"Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55:2000688.","journal-title":"Eur Respir J"},{"issue":"6","key":"432_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/jcm9061733","volume":"9","author":"A Borobia","year":"2020","unstructured":"Borobia A, Carcas A, Arnalich F, \u00c1lvarez-Sala R, Monserrat-Villatoro J, Quintana M, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020;9(6):1733.","journal-title":"J Clin Med"},{"key":"432_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2015.10.035","volume":"159","author":"R Sutherland","year":"2016","unstructured":"Sutherland R, Sindicich N, Entwistle G, Whittaker E, Peacock A, Matthews A, et al. Tobacco and e-cigarette use amongst illicit drug users in Australia. Drug Alcohol Depend. 2016;159:35\u201341.","journal-title":"Drug Alcohol Depend"},{"key":"432_CR14","unstructured":"Bowden-Jones O, Sulaiman Z, Sajid RH, Mp J. ACMD Advisory council on the misuse of drugs: ageing cohort of drug users. 2019."},{"key":"432_CR15","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA trendspotter briefingIImpact of COVID-19 on drug services and help-seeking in Europe. 2020 [cited 2020 Aug 12]. \n                  https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13073\/EMCDDA-Trendspotter-Covid-19_Wave-1-2.pdf\n                  \n                ."},{"key":"432_CR16","unstructured":"Comunidad de Madrid. Encuesta sobre impacto del COVID-19 en las pautas de consumo de drogas, los da\u00f1os y los servicios de drogas. 2020 [cited 2020 Aug 13]. \n                  https:\/\/www.comunidad.madrid\/sites\/default\/files\/doc\/sanidad\/drog\/encuesta_sobre_impacto_del_covid19.madrid_0.pdf\n                  \n                ."},{"issue":"5","key":"432_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.medcli.2018.05.011","volume":"151","author":"JB Soriano","year":"2018","unstructured":"Soriano JB, Rojas-Rueda D, Alonso J, Ant\u00f3 JM, Cardona PJ, Fern\u00e1ndez E, et al. The burden of disease in Spain: results from the Global Burden of Disease 2016. Med Clin. 2018;151(5):171\u201390.","journal-title":"Med Clin"},{"key":"432_CR18","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Spain country drug report 2019. 2019 [cited 2020 Aug 12]. \n                  https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11353\/spain-cdr-2019.pdf\n                  \n                ."},{"key":"432_CR19","unstructured":"Ministerio de Sanidad C y BS de E. INFORME 2019: Alcohol, tabaco y drogas ilegales en Espa\u00f1a. 2019. \n                  https:\/\/pnsd.sanidad.gob.es\/profesionales\/sistemasInformacion\/informesEstadisticas\/pdf\/2019OEDA-INFORME.pdf\n                  \n                ."},{"key":"432_CR20","unstructured":"Delegaci\u00f3n del Gobierno para el Plan Nacional sobre drogas. NATIONAL STRATEGY ON ADDICTIONS. 2017."},{"key":"432_CR21","unstructured":"Delegaci\u00f3n del Gobierno para el Plan Nacional sobre drogas. Memoria. Plan Nacional sobre Drogas. 2017."},{"key":"432_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102832","author":"J Chang","year":"2020","unstructured":"Chang J, Agliata J, Guarinieri M. COVID-19 - Enacting a \u2018new normal\u2019 for people who use drugs. Int J Drug Policy. 2020. \n                  https:\/\/doi.org\/10.1016\/j.drugpo.2020.102832\n                  \n                .","journal-title":"Int J Drug Policy"},{"key":"432_CR23","unstructured":"United Nations Development Programme (UNDP). COVID-19: new UNDP data dashboards reveal huge disparities among countries in ability to cope and recover|UNDP. 2020 [cited 2020 Aug 12]. \n                  https:\/\/www.undp.org\/content\/undp\/en\/home\/news-centre\/news\/2020\/COVID19_UNDP_data_dashboards_reveal_disparities_among_countries_to_cope_and_recover\/\n                  \n                ."},{"key":"432_CR24","unstructured":"World Drug Report 2019 [cited 2020 Aug 12]. \n                  https:\/\/wdr.unodc.org\/wdr2019\/\n                  \n                ."},{"key":"432_CR25","unstructured":"Dastmalchi LN. HIV in the era of COVID-19: why experts are concerned about an increase in cases\u2014ABC News [cited 2020 Aug 13]. \n                  https:\/\/abcnews.go.com\/Health\/hiv-era-covid-experts-concerned-increase-cases\/story?id=70331510\n                  \n                ."},{"key":"432_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-020-00370-7","volume":"17","author":"A Dunlop","year":"2020","unstructured":"Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17:26. \n                  https:\/\/doi.org\/10.1186\/s12954-020-00370-7\n                  \n                .","journal-title":"Harm Reduct J"},{"key":"432_CR27","unstructured":"International Network of People who Use Drugs (INPUD). INPUD Online survey on COVID-19 & People who use drugs (manuscript in preparation)."},{"key":"432_CR28","unstructured":"S\u00e1rosi P\u00e9ter. Harm reduction responses to COVID-19 in Europe: regularly updated infopage\u2014Drugreporter. 2020 [cited 2020 Aug 13]. \n                  https:\/\/drogriporter.hu\/en\/how-harm-reducers-cope-with-the-corona-pandemic-in-europe\/"},{"key":"432_CR29","unstructured":"UNAIDS. Worldwide more than half of new HIV infections now among key populations and their sexual partners [cited 2020 Aug 13]. \n                  https:\/\/www.unaids.org\/en\/resources\n                  \n                ."},{"issue":"5","key":"432_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","volume":"286","author":"JV Lazarus","year":"2019","unstructured":"Lazarus JV, Peric\u00e0s JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med. 2019;286(5):503\u201325. \n                  https:\/\/doi.org\/10.1111\/joim.12972\n                  \n                .","journal-title":"J Intern Med"},{"key":"432_CR31","unstructured":"WHO | Global health sector strategy on viral hepatitis 2016\u20132021. WHO. 2019 [cited 2020 Aug 13]. \n                  https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/\n                  \n                ."},{"key":"432_CR32","unstructured":"UNAIDS. Global AIDS report\u2014seizing the moment: tackling entrenched inequalities to end epidemidemics. 2020."},{"key":"432_CR33","unstructured":"World Health Organization. Rapid communication on the role of the GeneXpert \u00ae platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region European Laboratory Initiative on TB, HIV and Viral Hepatitis. 2020 [cited 2020 Aug 13]. \n                  https:\/\/apps.who.int\/bookorders\n                  \n                ."},{"issue":"6","key":"432_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/ADM.0000000000000346","volume":"11","author":"KT Phillips","year":"2017","unstructured":"Phillips KT, Anderson BJ, Herman DS, Liebschutz JM, Stein MD. Risk factors associated with skin and soft tissue infections among hospitalized people who inject drugs. J Addict Med. 2017;11(6):461\u20137.","journal-title":"J Addict Med"},{"key":"432_CR35","doi-asserted-by":"publisher","first-page":"108080","DOI":"10.1016\/j.drugalcdep.2020.108080","volume":"213","author":"J Doran","year":"2020","unstructured":"Doran J, Harris M, Hope VD, Wright T, Edmundson C, Sinka K, et al. Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: a comparative examination of data from two surveys. Drug Alcohol Depend. 2020;213:108080.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"432_CR36","doi-asserted-by":"publisher","first-page":"e0240011","DOI":"10.1371\/journal.pone.0240011","volume":"15","author":"JV Lazarus","year":"2020","unstructured":"Lazarus JV, Ratzan S, Palayew A, Billari FC, Binagwaho A, et al. COVID-SCORE: a global survey to assess public perceptions of government responses to COVID-19 (COVID-SCORE-10). PLoS ONE. 2020;15(10):e0240011.","journal-title":"PLoS ONE"},{"issue":"4","key":"432_CR37","doi-asserted-by":"publisher","first-page":"35621","DOI":"10.1136\/bmjopen-2019-035621","volume":"10","author":"JV Lazarus","year":"2020","unstructured":"Lazarus JV, Baker L, Cascio M, Onyango D, Schatz E, Smith AC, et al. Novel health systems service design checklist to improve healthcare access for marginalised, underserved communities in Europe. BMJ Open. 2020;10(4):35621.","journal-title":"BMJ Open"},{"issue":"1","key":"432_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, Bruneau J, Martin NK, \u00d8vrehus A, et al. (2019) Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20\u201330. \n                  https:\/\/doi.org\/10.1111\/liv.13949\n                  \n                .","journal-title":"Liver Int"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-020-00432-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T19:40:58Z","timestamp":1604518858000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00432-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00432-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-66726\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-66726\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CAP, JD, TS, MP and JC have no competing interests to report. JV reports Research grants and honoraria for lectures from Gilead Sciences, grants and personal fees from ViiV, grants from Merck, and grants from Janssen, outside the submitted work. EM reports grants and personal fees from Gilead, grants and personal fees from Cepheid, grants and personal fees from Abbott, and personal fees and a donation to IGTP from Abbvie, outside the submitted work. JVL reports reports grants, personal fees and other from AbbVie, MSD and Gilead Sciences, and personal fees from CEPHEID, GSK, Intercept, and Janssen, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}